Ketoconazole, a Cyp51 inhibitor clinically used for treating fungi infection (Strushkevich et al, 2010), reduced secretion of distal cholesterol precursors of the MSS-CRC CT26 and Caco2 cells without affecting cell survival in vitro (Appendix Fig. S6). This evidence concerns the gene CYP51A1 and fungal infectious disease.